Shirley Lehnert is currently a professor in the Department of Oncology at McGill University in Montreal, Quebec, Canada. She graduated from London University in the UK with a PhD in biophysics. Dr. Lehnert did postdoctoral work at the University of Rochester. She conducted research in radiobiology and biophysics first at Sloane Kettering Institute and then at the Radiological Research Laboratory of Columbia University in New York. Dr. Lehnert has published extensively in the fields of radiation biology, tumor biology, and drug delivery.

• Radiosensitization and Chemoradiation. Radiosensitization by Oxygen and Nitric Oxide. Radioenhancement by Targeting Cellular Redox Pathways and/or by Incorporation of High-Z Materials into the Target. Radiosensitization by Halogenated Pyrimidines. Radiosensitization by Antimetabolites. Radiosensitization by Platinum Drugs and Alkylating Agents. Topoisomerase Inhibitors and Microtubule-Targeting Agents. Targeting the DNA Damage Response: ATM, p53, Checkpoints, and the Proteasome. Radiosensitization by Inhibition of DNA Repair. Targeting Growth Factor Receptors for Radiosensitization. Targeting Signaling Molecules for Radiosensitization. Radiosensitization by Targeting the Tumor Microenvironment. Phytochemicals: Chemopreventive, Radiosensitizing, Radioprotective. Delivery Methods for Radioenhancing Drugs.

Shirley Lehnert is currently a professor in the Department of Oncology at McGill University in Montreal, Quebec, Canada. She graduated from London University in the UK with a PhD in biophysics. Dr. Lehnert did postdoctoral work at the University of Rochester. She conducted research in radiobiology and biophysics first at Sloane Kettering Institute and then at the Radiological Research Laboratory of Columbia University in New York. Dr. Lehnert has published extensively in the fields of radiation biology, tumor biology, and drug delivery.

• Radiosensitization and Chemoradiation. Radiosensitization by Oxygen and Nitric Oxide. Radioenhancement by Targeting Cellular Redox Pathways and/or by Incorporation of High-Z Materials into the Target. Radiosensitization by Halogenated Pyrimidines. Radiosensitization by Antimetabolites. Radiosensitization by Platinum Drugs and Alkylating Agents. Topoisomerase Inhibitors and Microtubule-Targeting Agents. Targeting the DNA Damage Response: ATM, p53, Checkpoints, and the Proteasome. Radiosensitization by Inhibition of DNA Repair. Targeting Growth Factor Receptors for Radiosensitization. Targeting Signaling Molecules for Radiosensitization. Radiosensitization by Targeting the Tumor Microenvironment. Phytochemicals: Chemopreventive, Radiosensitizing, Radioprotective. Delivery Methods for Radioenhancing Drugs.

Shirley Lehnert is currently a professor in the Department of Oncology at McGill University in Montreal, Quebec, Canada. She graduated from London University in the UK with a PhD in biophysics. Dr. Lehnert did postdoctoral work at the University of Rochester. She conducted research in radiobiology and biophysics first at Sloane Kettering Institute and then at the Radiological Research Laboratory of Columbia University in New York. Dr. Lehnert has published extensively in the fields of radiation biology, tumor biology, and drug delivery.

• Radiosensitization and Chemoradiation. Radiosensitization by Oxygen and Nitric Oxide. Radioenhancement by Targeting Cellular Redox Pathways and/or by Incorporation of High-Z Materials into the Target. Radiosensitization by Halogenated Pyrimidines. Radiosensitization by Antimetabolites. Radiosensitization by Platinum Drugs and Alkylating Agents. Topoisomerase Inhibitors and Microtubule-Targeting Agents. Targeting the DNA Damage Response: ATM, p53, Checkpoints, and the Proteasome. Radiosensitization by Inhibition of DNA Repair. Targeting Growth Factor Receptors for Radiosensitization. Targeting Signaling Molecules for Radiosensitization. Radiosensitization by Targeting the Tumor Microenvironment. Phytochemicals: Chemopreventive, Radiosensitizing, Radioprotective. Delivery Methods for Radioenhancing Drugs.